Diligence memo · auto-generated · as of July 2, 2026

Sera Prognostics, Inc.

Sera Prognostics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Sera Prognostics, Inc. operates in Other Health Care, based in SALT LAKE CITY.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Sera Prognostics, Inc. has raised $218M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $100M on 2021-02-23.

Most recent recorded round closed around 2021-02-23.

Valuation (modeled)modeled

Provath models Sera Prognostics, Inc. at approximately $2.0B (range $534M–$4.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.61× the median modeled value of Series D+ Other Health Care companies in 2019–2021 (26 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 99% of Other Health Care peers (5377 compared).

Modeled value ranks above 98% of those peers.

Closest niche peers: ZAHN Parent, LLC, Covetrus, Inc., EQH Parent, LLC, SonerMed, LLC, Fs Usme Lp.

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.